Our top pick for
Surface Oncology Inc is a biotechnology business based in the US. Surface Oncology shares (SURF) are listed on the NASDAQ and all prices are listed in US Dollars. Surface Oncology employs 51 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$7.70|
|52-week range||$5.06 - $14.40|
|50-day moving average||$6.80|
|200-day moving average||$7.12|
|Wall St. target price||$16.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.40|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-0.65%|
|1 month (2021-09-16)||28.12%|
|3 months (2021-07-16)||16.84%|
|6 months (2021-04-16)||13.40%|
|1 year (2020-10-16)||-18.26%|
|2 years (2019-10-16)||474.63%|
|3 years (2018-10-16)||8.39|
|5 years (2016-10-12)||N/A|
Valuing Surface Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Surface Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Surface Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Surface Oncology shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Surface Oncology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $23.3 million.
The EBITDA is a measure of a Surface Oncology's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$89.7 million|
|Operating margin TTM||24.15%|
|Gross profit TTM||$86.3 million|
|Return on assets TTM||7.52%|
|Return on equity TTM||13.86%|
|Market capitalisation||$352.3 million|
TTM: trailing 12 months
There are currently 3.6 million Surface Oncology shares held short by investors – that's known as Surface Oncology's "short interest". This figure is 1.8% up from 3.5 million last month.
There are a few different ways that this level of interest in shorting Surface Oncology shares can be evaluated.
Surface Oncology's "short interest ratio" (SIR) is the quantity of Surface Oncology shares currently shorted divided by the average quantity of Surface Oncology shares traded daily (recently around 434961.76115802). Surface Oncology's SIR currently stands at 8.29. In other words for every 100,000 Surface Oncology shares traded daily on the market, roughly 8290 shares are currently held short.
However Surface Oncology's short interest can also be evaluated against the total number of Surface Oncology shares, or, against the total number of tradable Surface Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Surface Oncology's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Surface Oncology shares in existence, roughly 80 shares are currently held short) or 0.104% of the tradable shares (for every 100,000 tradable Surface Oncology shares, roughly 104 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Surface Oncology.
Find out more about how you can short Surface Oncology stock.
We're not expecting Surface Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Surface Oncology's shares have ranged in value from as little as $5.055 up to $14.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Surface Oncology's is 1.6545. This would suggest that Surface Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Surface Oncology, Inc. , a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813, as well as a clinical trial collaboration with Roche Holding AG to evaluate SRF388. Surface Oncology, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.